{"id":"W4286602972","doi":"10.1200/jco.22.00221","title":"Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Royal Victoria Hospital; University of Toronto; University Health Network; McGill University; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Population; Gastroenterology; Lenvatinib; Phases of clinical research; Oncology; Immunotherapy; Toxicity; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003608563,0.0002953129,0.001846333,0.00034387,0.0001851793,0.00001839693,0.0002725964,0.0002734358,0.0001037817],"category_scores_gemma":[0.0007367804,0.0001720379,0.0003343614,0.0004523362,0.0001705039,0.0001011924,0.00006285254,0.0009993267,5.093671e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005658736,"about_ca_system_score_gemma":0.005092242,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001118653,"about_ca_topic_score_gemma":0.000210456,"domain_scores_codex":[0.9947486,0.0008082424,0.00279197,0.000401425,0.0008413247,0.0004084247],"domain_scores_gemma":[0.9947096,0.001098085,0.00320318,0.000266056,0.0004832021,0.0002399362],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6223753,0.07721262,0.005404952,0.0001366512,0.0005320674,0.0006825212,0.001966499,0.000008688543,0.002673917,0.00001683646,0.000233816,0.2887561],"study_design_scores_gemma":[0.2995183,0.6633577,0.004993401,0.000358168,0.0002547205,0.0002501477,0.002268022,0.0001656144,0.004574842,0.00006053908,0.02401107,0.0001875083],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.987153,0.0001816472,0.0000451743,0.003156756,0.0003488568,0.008955527,0.00001013385,0.00002302342,0.0001258584],"genre_scores_gemma":[0.9946283,0.00006112114,0.002442795,0.0005272862,0.0002600561,0.001358058,0.00001704325,0.00005388569,0.0006515229],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5861451,"threshold_uncertainty_score":0.9033418,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1226614338516699,"score_gpt":0.4658847024227313,"score_spread":0.3432232685710614,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}